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  IMPROVEMENTS IN DRUG DELIVERY 
 
[0001] The present invention relates to improvements in drug delivery.  
[0002] More particularly it relates to the use of Cell Penetrating Agents (CPA’s), and 
more particularly still to the use of Cell Penetrating Peptides (CPP’s) which have been stabilized 5 
by, for example: i) stapling two amino acids to form Stapled CPP’s (StaP’s) or ii) stitching three 
or more amino acids to form stitched CPP’s (StiP’s). 
[0003] These stabilized CPP’s are conjugated to a drug or Biologically Active Compound 
(BAC) directly or via a Bi-Functional Linker (BFL) so that the BAC can be carried though a cell 
membrane by the CPP. The resulting molecules are referred to as Drug Carrying Cell 10 
Penetrating Molecules (DCCPM’s).  
[0004] The preferred BAC’s delivered in this manner are oligonucleotides (ON’s), more 
preferably still electrically low charge carrying oligonucleotides (charge -3 to +3 at pH 7.5) and 
most preferably electrically neutral oligonucleotides (charge -1 to +1 at pH 7.5), such as, but not 
limited to, polynucleic acids (PNAs), phosphorodiamidate morpholino oligonucleotides (PMO’s) 15 
or modified derivatives thereof. 
[0005] The preferred BFL may be PEGylated, comprising poly ethylene glycol (PEG) 
groups including modifications such as an amine group, or incorporate a spacer, such as -Ala. 
These modifications can improve solubilisation or provide appropriate spacing between 
functional moieties. 20 
[0006] The invention also relates to a method of facilitating the uptake of a BAC into a 
cell, the use of a DCCPM in the treatment of a disease requiring alteration of an endogenous or 
exogenous gene, a method of improving the bioavailability of a drug or BAC, a method of 
introducing a drug or BAC to a site which is refractory to the drug or BAC in its native state, a 
method of treating a subject comprising administering the DCCPM’s of the invention and to a 25 
pharmaceutical composition comprising the DCCPM and one or more pharmaceutically 
acceptable excipients. 
[0007] Still further aspects will be apparent from the detailed description. 
 
BACKGROUND TO THE INVENTION 30 
 
[0008] In the treatment of all diseases it is desirable to deliver a drug or BAC into the body, and 
more preferably into a cell, at a target site, in a manner that ensures a maximal effect with 
minimal toxicity. This can be challenging. 
[0009] An example of drugs or BACs which are delivered in a targeted manner are 35 
oligonucleotides (ON’s), which term includes ON analogues. 
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[0010] ON’s can target essential DNA, RNA and protein sequences and can modulate gene 
expression in a number of ways that includes steric blocking to suppress (i) RNA splicing, (ii) 
protein translation or (iii) other nucleic acid:nucleic acid or nucleic acid:protein interactions. 
[0011]  Specifically, the hybridisation of ON’s to specific RNA sequence motifs prevents correct 
assembly of the spliceosome, so that it is unable to recognise the target exon(s) in the pre-5 
mRNA and hence excludes these exon in the mature gene transcript. Exclusion of an in-frame 
exon can lead to a truncated yet functional gene product; exclusion of an out of frame exon 
results in a frame-shift of the transcript, potentially leading to a premature stop codon and a 
reduction in the target gene expression level.  
[0012] Additionally, ON’s can be designed to target 5’ translation initiation start sites of viral 10 
gene transcript(s) to prevent binding of the translational machinery. Using antisense 
oligonucleotides (ASO) to suppress viral translation is a well-established technology1 and has 
progressed into clinical trials for viral haemorrhagic fevers such as Marburg and Ebola2,3.  
[0013] Also, ON’s can be designed to form aptamers such that the secondary and tertiary 
structures can bind proteins or other cellular targets thus impacting on specific gene expression 15 
levels or other cellular processes (e.g. post-translational modifications).  
[0014] An advantage of steric blocking based suppression over that of siRNA/RNAi based 
RNase H-induction of the RNA Induced Silencing Complex is the reduced likelihood of off target 
side effects.  
[0015] Modifications of an ON to produce a negatively charged backbone improve stability4-7, 20 
but these backbone chemistries e.g. 2’O-Methyl Phosphothioate analogues, elicit membrane 
toxicity issues, cause thrombocytopaenia and injection site problems upon clinical translation8, 
such that efficacy is prevented by toxicity issues, even when administration protocols become 
increasingly intermittent9.  
[0016] Indeed WO2013/150338 and WO 2014/053622 both disclose delivering negatively 25 
charged ON’s of small size (typically smaller than 1.5KDa) by complexing them with positively 
charged linear or stapled peptides of equal or greater than 15 amino acids and in the range of 
15-27 amino acids. 
[0017] JACS, Vol 136, 2014, GJ Hilnski et al, describe stapled and stitched peptides that are 
able to penetrate cells. Reference is made to the possibility that these peptides could be used to 30 
deliver an oligonucleotide, presumably in the same manner as disclosed in the international 
applications disclosed above, i.e. by complexation. There is nothing to suggest creating new 
entities of much larger size (greater than 1.5KDa, through 2.5KDa, 5KDa, 7.5KDa, 10KDa, 
12.5KDa or more) by covalently linking a BAC with a CPA, optionally via a BFL and indeed, the 
prior methodology requires the respective components to have opposite charges to facilitate 35 
complexing. 
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[0018] The use of electrically low charge carrying oligonucleotides (charge -3 to +3 at pH 7.5) 
and most preferably electrically neutral oligonucleotides (charge -1 to +1 at pH 7.5), such as, 
but not limited to, polynucleic acids (PNAs), phosphorodiamidate morpholino oligonucleotides 
(PMO’s), (covalently) conjugated directly or indirectly, using a BFL, was not apparent and 
indeed, limiting the charge on the ON further allows the use of smaller peptides (less than 15 5 
amino acids in length, through 14, 13, 12, 11, 10, 9, 8, 7, 6 to as few as 4 or 5) as carriers. 
[0019] The use of uncharged ON backbones, such as phosphorodiamidate morpholino 
oligonucleotides (PMOs), represent attractive BAC’s as they have an impeccable safety record 
in a preclinical and clinical setting.2,10-13 
[0020] However, their ability to penetrate cells and access their targets is compromised due to 10 
their uncharged nature14. 
[0021] Overcoming the problem of facilitating their entry into cells is therefore desirable. 
[0022] Over the last 20 years much research has been dedicated to developing CPA’s that 
facilitate delivery of drugs and BAC’s to the biological site of action. 
[0023] The approach has generally been to use charged peptides as non-covalent complexes 15 
to facilitate cell entry of a BAC. Conjugation has also been tried. 
[0024] W02014/064258 is an example of the existing conjugating art. A negatively charged ON 
is coupled to a targeting peptide via a linker. The targeting peptide is a receptor targeting 
moiety, and not a stapled or stitched peptide, and indeed considerable doubt exists as to 
whether DNA or RNA molecules can gain cell entry using a receptor targeting moiety as once a 20 
negatively charged ON is bound to such a moiety, non-covalent interactions alter its 
conformation15.  
[0025] WO89/03849 discloses oligonucleotide-polyamide conjugates. There is no disclosure of 
the use of stitched or stapled peptides. The methodology described uses oligonucleotides as a 
scaffold for the chain extension of peptides and not as a conjugate for delivery, per se. 25 
[0026] WO2011/131693 describes nucleic acid constructs which contain a nucleic acid specific 
for a given target gene and a selective inhibitor of a neurotransmitter transporter. There is no 
disclosure of the use of stitched or stapled peptides as a delivery agent. 
[0027] A peptide capable of effecting peptide-mediated cell delivery may also be referred to as 
a Cell Delivery Peptide (CDP). Examples include: poly arginine, penetratin (based upon an 30 
antennapedia homeodomain), or PMO internalization peptides (PIPs).  
[0028]  However, since their first description16 and given that many CPPs contain multiple 
arginines, β-alanine and 6-aminohexanoic acid residues, (e.g. poly-Arg12, TAT, Penetratin, 
Pip6a) [database maintained at http://crdd.osdd.net/raghava/cppsite/]17, it is surprising that no 
CPP-delivered drug has progressed through all phases of clinical trials. In part, this may be 35 
because the common arginine-rich core, which makes most CPP’s effective, also causes 
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membrane deformities18 and in higher mammals this manifests as prohibitive toxic side effects, 
such as tubular degeneration of the kidney19. 
[0029] At a physiological pH, and based on pKa of amino acid R groups, a formal charge (FC) 
can be calculated based on the formula: 
𝐹𝐶 = 𝑉 − 𝑁 −
𝐵
2
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Where, V = valence electrons of the neutral atom in isolation; N = the number of non-bonding 
valence electrons on the defined atom; B = the total number of electrons shared in bonds. 
[0030] Indeed, based on this, the CPPs typically used to date harbour many positively charged 
residues. It has been shown that there is a correlation between this positive charge and 
membrane toxicity20.  10 
[0031] Therefore, CPPs with a lower amount of positively charged residues within the amino 
acid sequence, whilst retaining the ability to cross a biological membrane, will be more clinically 
relevant. 
[0032] The Applicant has overcome this major impediment by utilising stabilized CPA’s. By 
linking a drug or BAC to a stabilized CPA, including stitched and stapled peptides, they have 15 
surprisingly obtained enhanced cellular uptake dynamics, 10-20 fold better than current state of 
the art for CPA’s21,22.  
[0033] They have illustrated this by delivering an ON targeted to repair a gene producing 
dystrophin. Targeting specific genes with ON is of course in itself known, as illustrated by, for 
example, WO2009/054725 and WO2010/123369. These publications however use a negatively 20 
charged backbone and deliver the cargo directly or using complexation. 
[0034] One way to prepare stapled and stitched peptides, two linked amino acids (stapled) or 
three or more linked amino acids (stitched), is to incorporate amino acids into the peptide that 
are modified to bear e.g. an olefin (alkene) group (which may be incorporated at defined relative 
positions during solid-phase peptide synthesis). For example, on-resin ring-closing metathesis is 25 
then used to close one (stapled [denoted as StaP herein]) or two or more (stitched [denoted as 
StiP herein]) all-hydrocarbon cross-links that induce the peptide to adopt a stabilised structure, 
typically, but not essentially an alpha helix. For StaP’s, it is preferred to use either one or both 
enantiomers of the un-natural amino acids, termed the S5 (S-pentenylalanine) or R5 (R-
pentenylalanine), or the S8 (S-octenylalanine) or R8 (R-octenylalanine), depending on the 30 
stereo-chemical configuration. For StiP’s, a further un-natural olefin-bearing α, α-di-substituted 
amino acid (B5 or B8) is utilised. Cross linking strategies are however not restricted to ring-
closing metathesis of un-natural olefin-bearing α, α-di-substituted amino acids. Other cross-
linking chemistry’s may be used to stabilize the peptide, such as ring-closing metathesis 
between O-allylserine analogues (S-OAS or R-OAS).  35 
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[0035] The cellular entry dynamics of existing CPAs and the StiP’s and StaP’s differ. Traditional 
CPPs enter cells via energy-independent direct plasma membrane translocation or via energy-
dependent, clathrin and caveolin-mediated endocytosis; whereas the StiP’s and StaP’s utilised 
in the invention enter via an energy dependent, but clathrin and caveolin independent 
mechanism 21,23. Given that StiP’s and StaP’s uptake is abrogated with reduced cellular 5 
decoration of heparin sulphate 21 a macropinocytotic entry mechanism is infered24, suggesting 
this altered entry mechanism enables enhanced cellular uptake and bio-distribution compared 
to the state of the art.  
[0036] Relative to their unmodified peptide precursors, StaP’s and StiP’s generally exhibit 
robust cellular uptake, significant resistance to proteolytic degradation, and in vivo stability that 10 
can support a half-life of more than 12 hours in non-human primates25. It is likely that this 
increase in drug-likeness stems from the highly rigidified structure and the burial of the 
backbone amide bonds in the core of e.g. the α-helix. This structural rigidity also decreases the 
likelihood that StiP’s and StaP’s will be immunogenic, as the design of major histocompatibility 
complexes is such that peptides must adopt an extended conformation to be presented. The 15 
potential reduced or lack of membrane toxicity and immunogenicity enhances the clinical 
translatability of compounds when conjugated to drugs and BAC’s such as ON’s. 
[0037] The BAC and CPP can be covalently conjugated directly, or covalently conjugated via a 
BFL. Many functional groups may be used for conjugation reactions.   
[0038] ONs can be used to induce a steric block to any gene in humans, animals and lower 20 
order organisms and thus can be applied to natural disease (including genetic and age-related 
diseases) or acquired diseases in humans and animals.  
[0039] For example, viral haemorrhagic fevers (VHFs) are animal-borne illnesses in which a 
prolonged inflammatory cytokine response leads to the gradual destruction of veins and 
arteries. Causes of VHF include Ebola and Marburg viruses and several Arena viruses; these 25 
diseases are presently considered untreatable.  Viral haemorrhagic fevers are characterized by 
high fever and bleeding disorders, and can cause death by shock and organ failure.  ASOs can 
be designed to target 5’ translation initiation start sites of viral gene transcript(s) to prevent 
binding of the translational machinery. Using ASO to suppress viral translation is a well-
established technology1 and has progressed into clinical trials for viral haemorrhagic fevers 30 
such as Marburg and Ebola2,3. One PMO, AVI-7537 was evaluated for human use in the West 
African Ebola outbreak in 2014-15. 
[0040] Some tissues are particularly refractory to naked PMO transfection, e.g. heart, which 
may reflect differential vesicle-mediated PMO uptake mechanisms23. In fact, direct intra-cardiac 
injection of naked PMO does not even lead to efficient transfection26, and refractory tissues tend 35 
to require repeat administration or high dose strategies27-29. However, whilst CPP conjugation 
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improves PMO bio-distribution and serum stability30-32, toxicity is still a major roadblock for 
pipeline development19. 
[0041] For effective clinical translation of steric blocking ASOs, CPPs need to effectively deliver 
the BAC to either the cytoplasm or nucleoplasm whilst limiting any toxicity associated with cell 
entry. 5 
[0042] Thus, providing DCCPM’s which are able to deliver a drug or BAC more efficiently or to 
a target site, or with lower toxicity and immunogenicity would be highly desirable. 
 
BRIEF SUMMARY OF THE DISCLOSURE 
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[0043] In accordance with a first aspect of the present invention there is provided a drug 
carrying cell penetrating molecule (DCCPM) comprising: 
i. a biologically active compound (BAC), and 
ii. a cell penetrating agent (CPA), which BAC and CPA are linked directly or 
via a bi-functional linker (BFL), 15 
and wherein the CPA is a stabilized peptide (CPP) which has a conformation 
imposed upon it by stapling to form a stapled peptide (StaP) or stitching to form a 
stitched peptide (StiP).  
[0044] A stapled peptide (StaP) may be formed by, for example, stapling two conformationally 
adjacent amino acids together, and a stitched peptide (StiP) may be formed by, for example, 20 
stitching at least three conformationally adjacent amino acids to form a stitched peptide (StiP). 
[0045] The stapling or stitching results in the formation of a cross link or bridge between two 
conformationally adjacent amino acids of the peptide. 
[0046] In a preferred embodiment the cross link or bridge comprises two components, a 
hydrocarbon bridge and a terminal methyl group. The hydrocarbon bridge may be composed of 25 
a double hydrocarbon bond or a single hydrocarbon bond. 
[0047] The CPP preferably comprises at least two un-natural amino acids bearing all-
hydrocarbon tethers (e.g. α-methyl,α-pentenyl glycine). 
[0048] The preferred stapled or stitched CPPs incorporate one or more of: a (S)-
pentenylalanine (S5) or its enantiomer (R5), a S-octenylalanine (S8) or its enantiomer (R8) or 30 
combinations thereof (e.g R-octenylalanine/S-pentenylalanine (R8/S5) or S-octenylalanine/R-
pentenylalanine (S8/R5). 
[0049] The preferred unnatural amino acids incorporated into the CPPs and reacted to form a 
cross link or bridge between them are illustrated in Table 1 and some exemplary and preferred 
resulting CPPs are illustrated in Table 2. 35 
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[0050] Table 1 
 
 
[0051] Table 2 5 
 
Entry Peptide Sequence Length Peptide Type 
3 TRQARRNRRRRWRRAAAA 18 Non RCM 
4 TRQARRNRRRRWRERQR 17 Non RCM 
5 RQIKIWFQNRRMKWKK 16 Non RCM 
6 RRRRRRRRWRRR 12 Non RCM 
7 LSQETFSDLWKLLPEN 16 Non RCM 
8 NQLKRSFFALRDQI 14 Non RCM 
9 NQLKRSFFALRDQI 14 Non RCM 
10 TILKASVDYIRKLQREQQRAKEL 23 Non RCM 
11 RRRRRRRRWRRR 12 Non RCM 
12 RRRRRRRRRRRR 12 Non RCM 
13 YGRKKRRQRRRP 12 Non RCM 
14 RKFKRLFQ 8 Non RCM 
15 NELKRSFFALRDQI 14 Non RCM 
16 NQL-R8-RS-FFAL-S5-DQI 14 Non RCM 
17 KNHTHQQDI 9 Non RCM 
18 
NELKRSFFALRDQIPSLQGEKASRAQILDKA
TEYIQYNLRRK 
42 Non RCM 
19 KATEYIQYNLRRKNHTHQQDIDDL 24 Non RCM 
20 ASTLFETFYLGGLLG 15 Non RCM 
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21 RRGSRPSGA-S5-RRR-S5-R 15 Non RCM 
22 FNINDRIKELGTLI 14 Non RCM 
23 
DHIKDSFHSLRDSVPSLQGEKASRAQILDK
ATEYIQYNLRRK 
42 Non RCM 
24 
EYIQYNLRKNHTHQQDIDDLKRQNALLEQQ
VRALGG 
36 Non RCM 
25 SSLFERFYNLVTPAGG 16 Non RCM 
26 NSSFADFFHTVPYNLL 16 Non RCM 
27 TRQARRN-S5-RRR-S5-RR 14 Non RCM 
28 RRGSRPSGA-S5-RRR-S5-RAAAA 19 i,i+4 Staple 
29 S5-RRQ-S5-RRDRQRRRRR 15 i,i+4 Staple 
30 TRQ-S5-RRQ-S5-RRRWRERQR 17 i,i+4 Staple 
31 SEELV-S5-EAH-S5-LCTLLENAIQDTVREQ 26 i,i+4 Staple 
32 SEELVAEAH-S5-LCT-S5-LENAIQDTVREQ 26 i,i+4 Staple 
33 SEELVAEAHNLCTLLE-S5-AIQ-S5-TVREQ 26 i,i+4 Staple 
34 DRRQRRR-S5-RQR-S5-RRR 15 i,i+4 Staple 
35 S5-RRQ-S5-RRRRQRRRRR 15 i,i+4 Staple 
36 S-S5-ELV-S5-EAHNLCTLLENAIQDTVREQ 26 i,i+4 Staple 
37 SEELVAEA-S5-NLC-S5-LLENAIQDTVREQ 26 i,i+4 Staple 
38 SEELVAEAHNLC-S5-LLE-S5-AIQDTVREQ 26 i,i+4 Staple 
39 SEELVAEAHNLCTLLENAI-S5-DTV-S5-EQ 26 i,i+4 Staple 
40 FS-S5-LWK-S5-L 8 i,i+4 Staple 
41 FM-S5-YWK-S5-L 8 i,i+4 Staple 
42 QTFS-S5-LWK-S5-L 10 i,i+4 Staple 
43 PPKKFR-S5-LFF-S5-S 12 i,i+4 Staple 
44 KK-pff-R-S5-LFF-S5-S 10 i,i+4 Staple 
45 RK-pff-S5-RLF-S5-SY 10 i,i+4 Staple 
46 RKF-S5-RLF-S5-SY 10 i,i+4 Staple 
47 R-pff-K-S5-RLF-S5-SY 10 i,i+4 Staple 
48 AM-S5-YWK-S5-L 8 i,i+4 Staple 
49 QTFSD-R5-WK-S5-L 10 i,i+4 Staple 
50 KKFR-S5-LFF-S5-S 10 i,i+4 Staple 
51 RRLFR-S5-NLFL-S5-T 12 i,i+4 Staple 
52 RR-pff-S5-RLF-S5-SY 10 i,i+4 Staple 
53 RKA-S5-RLF-S5-SY 10 i,i+4 Staple 
54 RK-pff-S5-RLF-S5-SY 10 i,i+4 Staple 
55 S5-RLF-S5-SY 7 i,i+4 Staple 
56 KQKRKFS-S5-FFK-S5-L 13 i,i+4 Staple 
57 KQKRK-pff-S-S5-FFK-S5-L 13 i,i+4 Staple 
58 KQKRK-pff-S-S5-FFK-S5-L 13 i,i+4 Staple 
59 KF-S5-RLF-S5 7 i,i+4 Staple 
60 S5-RLF-S5 5 i,i+4 Staple 
61 RKF-S5-RLF-S5 8 i,i+4 Staple 
62 KQKRKFS-S5-FFK-S5-LV 13 i,i+4 Staple 
63 KQ-pff-RKKS-S5-FFK-S5-L 13 i,i+4 Staple 
64 RK-pff-S5-RLF-S5 8 i,i+4 Staple 
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65 F-S5-RLF-S5 6 i,i+4 Staple 
66 KTYRGAFQ-S5-LFQ-S5-VRE 16 i,i+4 Staple 
67 STALR-S5-LIE-S5-LVNITQNQKAPL 22 i,i+4 Staple 
68 STALRELI-S5-ELV-S5-ITQNQKAPL 22 i,i+4 Staple 
69 STALRELIEEL-S5-NIT-S5-NQKAPL 22 i,i+4 Staple 
70 NELK-S5-SFF-S5-LRDQIPELENNEKAP 24 i,i+4 Staple 
71 LENRQ-S5-KLE-S5-ANRHLL 16 i,i+4 Staple 
72 IL-S5-ASV-S5-YIRKLQREQ 16 i,i+4 Staple 
73 FNI-S5-DRI-S5-ELGTLI 14 i,i+4 Staple 
74 KN-S5-THQ-S5-DI 9 i,i+4 Staple 
75 STALRELIEE LV-S5-ITQ-S5-QKAPL 21 i,i+4 Staple 
76 NELK-S5-SFF-S5-LRDQI 14 i,i+4 Staple 
77 LENRQKKLE-S5-ANR-S5-LL 16 i,i+4 Staple 
78 ILKAS-S5-DYI-S5-KLQREQ 16 i,i+4 Staple 
79 DHIK-S5-SFH-S5-LRDSV 14 i,i+4 Staple 
80 DHIKDSF-S5-SLR-S5-SV 14 i,i+4 Staple 
81 
S5-YIQ-S5-
NLRRKNHTHQQDIDDLLKRQNALLEQQVR
ALGG 
38 i,i+4 Staple 
82 TYRGAAQ-S5-AAQ-S5-VREV 16 i,i+4 Staple 
83 TY-S5-GAF-S5-NLFQSVREV 16 i,i+4 Staple 
84 A-S5-SVF-S5-NYFHSVPYFEL 17 i,i+4 Staple 
85 GAF-S5-NLF-S5-SV 10 i,i+4 Staple 
86 S5-GAF-S5-NLF-R5-SV 11 i,i+4 Staple 
87 SYRGAFQ-S5-LFQ-S5-VREV 16 i,i+4 Staple 
88 SSVFY-S5-YFH-S5-VPYFEL 16 i,i+4 Staple 
89 A-S5-TLF-S5-TFYLGGLLG 15 i,i+4 Staple 
90 S5-GAF-S5-NLFQSV 11 i,i+4 Staple 
91 A-S5-SSF-S5-DFFHTVPYNLL 17 i,i+4 Staple 
92 ERLRRRI-S5-LCR-S5-HHST 16 i,i+4 Staple 
93 ERLRRRI-S5-NLCR-S5-HHST 17 i,i+4 Staple 
94 ERLRRRL-S5-LCR-S5-HHST 16 i,i+4 Staple 
95 ERLRRRF-S5-LCR-S5-HHST 16 i,i+4 Staple 
96 ERFRRRI-S5-LCR-S5-HHST 16 i,i+4 Staple 
97 ERLARRI-S5-LCR-S5-HHST 16 i,i+4 Staple 
98 ENPESILD-S5-HVQ-S5-VM 15 i,i+4 Staple 
99 PE-S5-ILD-S5-HVQRVM 13 i,i+4 Staple 
100 ERLRRRI-S5-FCR-S5-HHST 16 i,i+4 Staple 
101 ERLRRRNL-S5-LCR-S5-HHST 17 i,i+4 Staple 
102 ERNLRRRI-S5-LCR-S5-HHST 17 i,i+4 Staple 
103 ERWRRRI-S5-LCR-S5-HHST 16 i,i+4 Staple 
104 RELRREI-S5-LCR-S5-HHST 16 i,i+4 Staple 
105 ENPE-S5-ILD-S5-HVQRVM 15 i,i+4 Staple 
106 NPE-S5-ILD-S5-HVQRVM 14 i,i+4 Staple 
107 WPE-S5-ILD-S5-HVQRVM 14 i,i+4 Staple 
108 PE-S5-ILD-S5-HVRRVMR 14 i,i+4 Staple 
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109 RPE-S5-ILD-S5-HVRRVMR 15 i,i+4 Staple 
110 TRQA-R8-RNRRRR-S5-RR 14 i,i+7 Staple 
111 RRGSRPSGA-R8-RRRRRA-S5 17 i,i+7 Staple 
112 RRGSRPSGA-R8-RRRRRA-S5-AA 19 i,i+7 Staple 
113 TRQARRN-R8-RRRWRE-S5-QR 17 i,i+7 Staple 
114 RRRR-R5-RRRWRR-S8 12 i,i+7 Staple 
115 KPE-S5-ILD-S5-HVQRVM 14 i,i+7 Staple 
116 WPE-S5-ILD-S5-HVRRVMR 15 i,i+7 Staple 
117 RRRR-R8-RQRRRR-S5-RR 14 i,i+7 Staple 
118 RRGSRPSGA-R8-RRRRRR-S5 17 i,i+7 Staple 
119 R8-RRQRRR-S5-RQRRRRR 15 i,i+7 Staple 
120 TRQARRN- R5-RRRWRE-S8-QR 17 i,i+7 Staple 
121 RRRR-R5-RRRRRR-S8 12 i,i+7 Staple 
122 YGRK-R5-RRQRRR-S8 12 i,i+7 Staple 
123 S-R8-ELVAEA-S5-NLCTLLENAIQDTVREQ 25 i,i+7 Staple 
124 SEELVAEAH-R8-LCTLLE-S5-AIQDTVREQ 26 i,i+7 Staple 
125 SEELVAEAHNLCT-R8-LENAIQ-S5-TVREQ 26 i,i+7 Staple 
126 RQIKIW-R5-QNRRMK-S8-KK 16 i,i+7 Staple 
127 RRRR-R5- RRRWRR-S8 12 i,i+7 Staple 
128 S-R8-ELVAEA-S5-NLCTLLENAIQDTVREQ 26 i,i+7 Staple 
129 SE-R8-LVAEAH-S5-LCTLLENAIQDTVREQ 26 i,i+7 Staple 
130 SEELVAEAHNLC-R8-LLENAI-S5-DTVREQ 26 i,i+7 Staple 
131 SEELVAEAHNLCTLLE-R8-AIQDT V-S5-EQ 26 i,i+7 Staple 
132 LSQETF-R8-DLWKLL-S5-EN 16 i,i+7 Staple 
133 ILR-R8-AVSHMK-S5-LRGT 15 i,i+7 Staple 
134 ILR-R8-AVSHMK-S5-LRGT 15 i,i+7 Staple 
135 NEL-R8-RS FRSL-S5-DSI 14 i,i+7 Staple 
136 NEL-R8-RS FRAL-S5-DQI 14 i,i+7 Staple 
137 NEL-R8-RS FFAL-S5-DSI 14 i,i+7 Staple 
138 NEL-R8-RS FFAL-S5-DQI 14 i,i+7 Staple 
139 IL-R8-MA-VSHM-S5-SLRGT 15 i,i+7 Staple 
140 NEL-R8-RS FRAL-S5-DSI 14 i,i+7 Staple 
141 NEL-R8-RS FFSL-S5-DQI 14 i,i+7 Staple 
142 WNEL-R8-RSFRSL-S5-DQI 15 i,i+7 Staple 
143 NQR-R8-LSFFAL-S5-DQI 14 i,i+7 Staple 
144 NQL-R8- RSFFAL-S5-DQI 14 i,i+7 Staple 
145 NQR-R8- LSFFAL-S5-DQI 14 i,i+7 Staple 
146 NQL-R8- LSFFAR-S5-DQI 14 i,i+7 Staple 
147 NKL-R8-RS FFAL-S5-DQI 14 i,i+7 Staple 
148 NEL-R8-RS FFAL-S5-DQI 14 i,i+7 Staple 
149 NELK-R8-SFFALR-S5-QIPELENNEKAP 24 i,i+7 Staple 
150 AHL-R8- LCLEKL-S5-GLV 14 i,i+7 Staple 
151 NQL-R8-RSFFAL-S5-DQI (D-amino acids) 14 i,i+7 Staple 
152 IQD-S5-LAFFSR-R8-LQN (D-amino acids) 14 i,i+7 Staple 
153 NKL-R8-RS-FKAL-S5-KQI 14 i,i+7 Staple 
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154 NELK-R8-S-FFALR-S5-QI 14 i,i+7 Staple 
155 NQL-R8-RS-FFAL-S5-DQIPELENNEKAP 24 i,i+7 Staple 
156 NQL-R8-RSFFAL-S5-DQI 14 i,i+7 Staple 
157 AHL-R8-LCLEKL-S5-GLV-(K-(PEG)1- 15 i,i+7 Staple 
158 KV-R8-ILK KAT-S5-YILS 14 i,i+7 Staple 
159 R8-KR RAHA-S5-AERARR 14 i,i+7 Staple 
160 IQD-S5-LAFFSR-R8-LQN (D-amino acids) 14 i,i+7 Staple 
161 NQL-R8-RSFFAL-S5-DQI (D-amino acids) 14 i,i+7 Staple 
162 NQL-R8-RS-FFAL-S5-DQI 14 i,i+7 Staple 
163 NQL-R8-RSFFAL-S5-DQI 14 i,i+7 Staple 
164 EENAKRR-R8-HNALER-S5-RR 17 i,i+7 Staple 
165 NQL-R8-FSRFAL-S5-DQI(D-amino acids) 14 i,i+7 Staple 
166 NQL-R8-LS-S5-DQI 10 i,i+7 Staple 
167 NQL-R8-FS-S5-DQI 10 i,i+7 Staple 
168 TILKASVDYI RKL-R8-REQQRA-S5-EL 23 i,i+7 Staple 
169 FNI-R8-DRI-S5-TLI 11 i,i+7 Staple 
170 RNI-R8-DRI -S5-TRI 11 i,i+7 Staple 
171 KATEYIQYNLRRKN-R8-THQQDI-S5-DL 24 i,i+7 Staple 
172 NEL-R8-RSFFAL-S5-DQIDQIPAAKRVKLD 26 i,i+7 Staple 
173 NQL-R8-RSFFAL-S5-DQI 14 i,i+7 Staple 
174 RNI-R8-DRIKEL-S5-TLI 14 i,i+7 Staple 
175 FNIN-R8-RIKELG-S5-LI 14 i,i+7 Staple 
176 FNI-R8-DRIKEL-S5-TRI 14 i,i+7 Staple 
177 NQL-R8-RS FRAL-S5-DQI 15 i,i+7 Staple 
178 NEL-R8-RSFFAL-S5-DQIDQIPKKKRKV 24 i,i+7 Staple 
179 ENPE-R8-ILDEHV-S5-RVM 15 i,i+7 Staple 
180 S8-RQARRN-B5-RRRWRE-S8-QR 16 
i,i+4, i+11 Stitch 
Reduced 
181 TRQ-S5-RRN-B5-RRRWRE-S8-QR 17 i,i+4, i+11 Stitch 
182 TRQ-S5-RRA-B5-RRRWRE-S8-QR 17 i,i+4, i+11 Stitch 
183 S5-RRN-B5-RRRWRE-S8 12 i,i+4, i+11 Stitch 
184 
EYIQ-R5-NLRRKNH-S8-
HQQDIDDLKRQNALLEQQVRALGG 
37 i,i+4, i+11 Stitch 
185 S8-RQARRQ-B5-RRRWRE-S8-QR 17 
i,i+4, i+11 Stitch 
Reduced 
186 TRQ-S5-Q-B5-RRRWRE-S8-QR 15 i,i+4, i+11 Stitch 
187 TRQ-S5-RRN-B5-RRRWRE-S8-QR 17 
i,i+4, i+11 Stitch 
Reduced 
188 R8-RQARRN-B5-RRRWRE-S8-QR 17 
i,i+4, i+11 Stitch 
Reduced 
189 R8-RQARRQ-B5-RRRWRE-S8-QR 17 i,i+4, i+11 Stitch 
190 S5-RRN-B5-RRRWRR-S8 12 i,i+4, i+11 Stitch 
191 RRA-B5-RRRWRR-S8 11 i,i+4, i+11 Stitch 
192 S5-RRR-B5-RRRRRR-S8 12 i,i+4, i+11 Stitch 
193 S5-KIW-B5-QNRRNLK-S8 13 i,i+4, i+11 Stitch 
194 S5-RRR-B5-RRRRRR-S8 12 i,i+4, i+11 Stitch 
195 S5-GRK-B5-RRQRRR-S8 12 i,i+4, i+11 Stitch 
196 S5-RRQ-B5-RRRWRR-S8 12 i,i+4, i+11 Stitch 
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197 S5-RRR-B5-RRRWRR-S8 12 i,i+4, i+11 Stitch 
198 RQ-S5-KIW-B5-QNRRMK-S8-KK 16 i,i+4, i+11 Stitch 
199 S5-KIW-B5-QNRRAK-S8 12 i,i+4, i+11 Stitch 
200 S5-RRR-B5-RRRWRR-S8 12 i,i+4, i+11 Stitch 
201 L-S5-ILQ-B5-AVQVIL-S8-LEQQVRER 21 i,i+4, i+11 Stitch 
202 LLILQQAV-S5-VIL-B5-LEQQVR-S8-R 21 i,i+4, i+11 Stitch 
203 S5-DFS-B5-YWK-R5-L 10 i,i+4, i+11 Stitch 
204 LS-S5-ETF-B8-DLWKLL-S8-EN 16 i,i+4, i+11 Stitch 
205 LSQ-S5-TFS-B8-LWKLLA-S8-N 16 i,i+4, i+11 Stitch 
206 L-S5-ILQ- B5-AVQ-R5-ILGLEQQVRER 21 i,i+4, i+11 Stitch 
207 LLILQQAV-S5-VIL-B5-LEQ-R5-VRER 21 i,i+4, i+11 Stitch 
208 LLIL-S5-QAV-B5-VIL-R5-LEQQVRER 21 i,i+4, i+11 Stitch 
209 R5-DFS-B5-YWK-S5-L 10 i,i+4, i+11 Stitch 
210 LS-S5-ETA-B8-DLWKLL-S8-EN 16 i,i+4, i+11 Stitch 
211 EDIIRNIA- S5-HLA-B5-VGDWNLD-S8-SI 23 i,i+4, i+11 Stitch 
212 
NIA-S5-HLA-B5-VGDWNLD- S8-SI (isomer 
2) 
18 i,i+4, i+11 Stitch 
213 S5-HLA-B5-VGDWNLD-S8 (isomer 1) 13 i,i+4, i+11 Stitch 
214 
NVKRR-R8-HNVLER-S5-RRNEL-R8-
RSFFAL-S5-DQI 
29 i,i+4, i+11 Stitch 
215 
S5-YIQ-B5-NLRRKNH-S8-
HQQDIDDLLKRQNALLEQQVRALGG 
38 i,i+4, i+11 Stitch 
216 NIA-S5-HLA-B5-VGDWNLD-S8-SI 18 i,i+4, i+11 Stitch 
217 NIA-S5-HLA-B5-VGDWNLD-S8 16 i,i+4, i+11 Stitch 
218 S5-HLA-B5-VGDWNLD-S8 13 i,i+4, i+11 Stitch 
219 
EYIQYNLR-S5-KNH-B5-HQQDID-S8-
LKRQNALLEQQVRALGG 
37 i,i+4, i+11 Stitch 
 
S5= a-methyl, a-alkenylglycine with 5 carbon chain 
S8= a-methyl, a-alkenylglycine with 8 carbon chain  
B5= a-methyl, a-alkenylglycine with two 5 carbon chain 
 5 
[0052] Alternative CPPs and their method of manufacture are disclosed in Chu et al, 2014 and 
associated supplementary information, and are incorporated by reference21. 
[0053] The exemplified stabilized peptide comprises two or more olefin bearing side chains that 
are covalently formed, typically by means of a ring-closing metathesis. 
[0054] The stabilized conformation typically comprises at least one alpha helix. It may however, 10 
in the alternative, comprise at least one turn (for example, but not limited to, α, β, γ, δ or π), 
several turns to form a beta sheet, or a combination of one or more of: an alpha helix, turn, or 
beta sheet. 
[0055] The formal charge of a CPP is calculated at physiological pH (about 7.5) and is based 
on the pKa of amino acid R groups. These values (pKx) are represented in Table 3. 15 
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[0056] Table 3 
 
 
[0057] CPPs typically used to date harbour many positively charged residues. Reducing the 
amount of positively charged residues within the amino acid sequence, whilst retaining the 5 
ability to cross a biological membrane, will be more clinically relevant.  
[0058] Accordingly, it is possible to reduce the charge on the peptide sequences illustrated in 
Table 2. 
[0059] The preferred BAC is an oligonucleotide (ON), more preferably still an anti-sense 
oligonucleotide (AON). Different anti-sense oligonucleotide chemistries are illustrated in Table 4, 10 
with the use of low charge or neutral charged chemistries, such as, phosphorodiamidate 
morpholino oligonucleotides (PMOs) being preferred. 
 
[0060] Table 4 
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[0061] The BAC may target and alter the expression of an endogenous or exogenous gene. 
Endogenous gene targets include but are not limited to genes associated with neuromuscular 
disease, metabolic disease, cancer, age-related degenerative diseases, and exogenous gene 5 
targets include those of an acquired disease e.g. viral infections. 
[0062] Whilst the BAC may be linked to the CPP directly the Applicant has found the use of a 
BFL desirable. Exemplary, non-limiting BFL chemistries are illustrated in Table 5. 
 
[0063] Table 5 10 
 15 
 
Entry Linker (L) 
Linker 
acronym 
is present 
Z Y3 
1 
 
SMCC 
 
 
or not present 
2 
 
AMAS 
 
 
or not present 
3 
 
BMPS 
 
 
or not present 
4 
 
GMPS 
 
 
or not present 
5 
 
DMVS 
 
 
or not present 
6 
 
EMCS 
 
 
or not present 
7 
 
LC-SMCC 
 
 
or not present 
8 
 
SM(PEG)n 
 
 
or not present 
9 
 
DSG Not present 
 
or not present 
10 
 
DSCDS Not present 
 
or not present 
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11 
 
HNA Not present 
 
or not present 
 
[0064] By way of a footnote to Table 5, the following should be noted: 
[0065] Figure 5A highlights general structure of a DCCPM where the following are preferred, 
but not limited to the following defined atoms or groups. 
[0066] In a preferred embodiment illustrated in figure 5C, where Y1= Nitrogen, Y2 = Hydrogen, 5 
Y3 = spacer such as (PEG)n n=5, but not limited to those identified in Table 5, Z = a sulfur 
containing moiety e.g. Cysteine and L = BFL such as SMCC 
[0067] Other embodiments may utilize variations over the structure shown in Figure 5A. For 
example if another embodiment does not require a thiol for conjugation of the BFL to the CPA 
as illustrated in Figure 5D, then Z = Y3  where Y3 is a spacer in Table 5. For a BFL that does 10 
not require a sulphur for conjugation of the BAC and CPA e.g. not limited to entries 9-11 in 
Table 5  Z= a covalent bond between L and Y3 
[0068] Other embodiments may not require the use of a spacer, a BFL and as such a thiol 
group for the formation of a DCCPM depicted in Figure 7 then the following apply. If no spacer 
is utilized then Y3 can represent a covalent bond between Y1 and the BAC in which case Z and 15 
L = Y1 where Y1 is a N terminus of the CPA. 
[0069] These chemistries may be further expanded and Table 6 exemplifies modifications to 
amino acids via which functional groups can be introduced to provide desirable properties to the 
DCCPM. These will include, but are not limited to, an acetyl, a cholesterol, a fatty acid, a 
polyethylene glycol, a polysaccharide, an aminoglycan, a glycolipid, a polyphenol, a nuclear 20 
localising signal, a nuclear export signal, an antibody, and a targeting molecule. 
 
[0070] Table 6. 
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[0071] A preferred linker chemistry utilises an amine to sulphydryl cross linker containing N- 
hydroxysuccinimide esters and malemide reactive groups separated by a cyclohexane spacer 
namely succinimidyl 4-(N-maleimidomethyl) cyclohexane-1-carboxylate (SMCC) to form a 
covalent bond between the BFL and the CPP. 5 
[0072] A schematic intermediate compound using SMCC as the BFL and the resultant DCCPM 
is depicted in Fig 5b. 
[0073] In a particularly preferred embodiment the linker may incorporate polyethylene glycol in 
single or multiple units (PEG)n, where n=1 to 10 PEG molecules. 
[0074] Hereafter, where the CPP comprises the sequence RKF-S5-RLF-S5 and the BFL is a 10 
PEGylated SMCC, the resultant compound is termed CP8M. 
[0075] Where the CPP comprises the sequence RKF-S5-RLF-S5 and the BFL is a PEGylated 
hydrazynal nicotinic acid (HNA), the resultant compound is termed HP8M. 
[0076] Where the CPP comprises the sequence RKF-S5-RLF-S5 and the BFL is SMCC, the 
resultant compound is termed C8M. 15 
[0077] Thus a CPA, such as Compound III (Fig 5b) may be covalently linked to a BFL, if 
required, preferentially incorporating (PEG)n where n=1-10. 
[0078]  Covalent linkage to the CPP may be via, for example, but not limited to, a β-ala or any 
other suitable moiety.  
[0079] In the preferred embodiment, the (PEG)n is linked using a sulphur containing molecule 20 
e.g. cysteine, to enable covalent coupling as a PEGylated (SMCC). This in turn is covalently 
linked to a functional group on the BAC, in the preferred embodiment a primary amine, 
(Compound I), thus generating a DCCPM (Compound V). 
[0080] According to a second aspect of the invention there is provided a method for facilitating 
the uptake of a biologically active compound (BAC) into a cell by the conjugation of the 25 
biologically active compound, directly or via a bi-functional linker (BFL), to a cell penetrating 
agent (CPA) which is a stabilized peptide which has a conformation imposed upon it by stapling 
to form a stapled peptide (StaP) or stitching to form a stitched peptide (StiP), to form a drug 
carrying cell penetrating molecule (DCCPM) and presenting said DCCPM to said cell in a 
suitable vehicle.  30 
[0081] Where HNA has been incorporated into the terminal end of the CPP, to form a DCCPM 
in which the BAC is an ON, the ON has been modified to incorporate 4 formyl benzioic acid to 
facilitate covalent conjugation. 
[0082] According to a third aspect of the present invention there is provided a DCCPM of the 
first aspect of the invention for use in the treatment of a disease requiring alteration of the 35 
expression of an endogenous or exogenous gene. 
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[0083] The DCCPM may be used in the treatment of a, for example, neuromuscular disease, 
metabolic disease, cancer, age-related degenerative disease or to treat an acquired viral 
infection.  
[0084] In one embodiment the DCCPM is used in the treatment of a muscular dystrophy e.g. 
Duchenne muscular dystrophy (DMD) although the skilled person will readily appreciate that the 5 
invention can be used to target a wide range of genes. 
[0085] In the case of DMD the DCCPM may comprise an AON targeting exon 51 of the 
dystrophin gene. 
[0086] In accordance with a fourth aspect of the present invention there is provided a method of 
improving the bioavailability of a drug or BAC comprising linking the drug or BAC to a CPP 10 
which is a stabilized peptide which has a conformation imposed upon it by stapling to form a 
stapled peptide (StaP) or stitching to form a stitched peptide (StiP). 
[0087] In accordance with a fifth aspect of the present invention there is provided a method of 
introducing a drug or BAC to a site which is refractory to a drug or BAC in its native state 
comprising linking the drug or BAC to a CPP which is a stabilized peptide which has a 15 
conformation imposed upon it by stapling to form a stapled peptide (StaP) or stitching to form a 
stitched peptide (StiP) and administering it to a subject. 
[0088] The DCCPMs of the invention can be used to administer the drug or BAC to a target 
tissue, such as, for example the heart, brain or muscle. 
[0089] In accordance with a sixth aspect of the present invention there is provided a method of 20 
treating a subject to alter the expression of an endogenous or exogenous gene comprising 
administering a DCCPM of the invention to a subject. 
[0090] In accordance with a seventh aspect of the present invention there is provided a 
composition comprising a DCCPM of the invention and one or more pharmaceutically 
acceptable excipients enabling the composition to be administered orally, parenterally, 25 
intravenously or topically.  
 
BRIEF DESCRIPTION OF THE DRAWINGS 
 
[0091] Embodiments of the invention are further described hereinafter with reference to the 30 
accompanying Drawings, in which: 
[0092] Fig 1a-c show a general schematic of a CPP which it has been stabilized by means of 
the incorporation of olefin-bearing α, α-di-substituted amino acids that permit a further chemical 
modification such that a cross link can be formed. Cross linking of two such non-natural amino 
acids is termed stapling; cross linking involving more than two non-natural amino acids is 35 
termed stitching. This schematic can be referenced against Tables 1 and 2 of this application. 
[0093] Fig 1a is an example of a non-cyclised and an i,i+4 ring closing metathesis (RCM) using 
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Grubb’s Gen 1 catalyst to form an StaP CPA; 
[0094] Fig 1b is an example of a reduced RCM StaP using conventional reduction chemistry; 
[0095] Fig 1c is a schematic showing a selection of different StaP or StiP RCM configurations 
and their corresponding starting positions; 
[0096] Fig 2 exemplifies the structures of charge variants: 3+ (CP8M-3), 2+ (CP8M-2), 1+ 5 
(CP8M-1) and 0+ (CP8M-0) illustrating relative positions of charge on the StaP, however the 
positions and charge can be varied in any permutation or combination; 
[0097] Fig 3 exemplifies the structure of an amino acid which can be incorporated into StaP or 
StiPs with varying functional groups as defined in Table 6. The functional groups can then be 
used for bio-conjugation; 10 
[0098] Fig 4a is a representation of a RCM reaction to form a StaP; 
[0099] Fig 4b shows the resulting CD spectrum of the StaP and non-cyclised stating peptide; 
[00100] Fig 4c is a COSY NMR spectra of CP8M; 
[00101] Fig 4d is a NOESY NMR Spectra of CP8M; 
[00102] Fig 4e is a TOCSY NMR spectra of CP8M; 15 
[00103] The Spectra were collected at room temperature in H2O spiked with 10% D2O 
and 10 mM sodium acetate; 
[00104] Fig 5a is a schematic diagram of StaP DCCPM depicting variants of linkers and 
spacers as defined in Table 5;  
[00105] Fig 5b is a schematic diagram of DCCPM depicting the synthetic steps for the 20 
conjugation of a StaP to a PMO. The PMO is modified to yield a 5’ amine group (compound I); 
the heterobifunctional protein crosslinker Succinimidyl-4-[N-maleimidomethyl] cyclohexane-1-
carboxylate (SMCC; compound II) is attached to 5’ amine group to yield compound IV; an i,i+4 
stapled peptide (compound III) is conjugated  to generate the final DCCPM (compound V);  
[00106] Fig 5c is a DCCPM of CP8M conjugated to an ON using a SMCC linker (e.g. 25 
PMO-CP8M); 
[00107] Fig 5d is a DCCPM of HP8M using a HNA linker (PMO-HP8M); 
[00108] The FITC group here and elsewhere may be any other fluorescent label and is 
present merely to enable visualization; 
[00109] Fig 6 shows a general schematic of a FITC labeled DCCPM in which the n-30 
termini of the FITC labelled PMO (compound I) and the CPA (compound III) are linked via a bi-
functional linker disuccinimidyl glutarate (DSG) forming compound VI;  
[00110] Fig 7 shows a general schematic diagram of  a DCCPM in which a FITC labelled 
PMO is directly conjugated to a CPA through a shared nitrogen forming compound VII;  
[00111] Figs 8a-o show the liquid chromatography-mass spectrometry conformation of 35 
the synthetic steps and the molecular masses of compounds depicted in Fig 1, Fig 2 and Fig 5. 
All PMOs in this application are fluorescently labelled unless specified otherwise. 
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[00112] Fig 8a is a LRMS(API-ES) mass spectra of CP8M-NC. Mass calculated for 
C76H130N18O16S
2+ (M+2H)2+ 791.5  found 791.8; 
[00113] Fig 8b is a LRMS(API-ES) mass spectra of CP8M. Mass calculated for 
C74H125N18O16S
+ (M+H)+ 1554.9 found 1554.5; 
[00114] Fig 8c is a LRMS(API-ES) mass spectra of C8M. Mass calculated for 5 
C59H95N16O10S
+ (M+H)+ 1220.5 found 1220.1; 
[00115] Fig 8d is a LRMS(API-ES) mass spectra of HP8M. Mass calculated for 
C77H125N20O16
+ (M+H)+ 1586.9 found 1586.5; 
[00116] Fig 8e is a HRMS(LQT-ESI) mass spectra of PMO. Mass calculated for 
C332H500N153O110P25
 (M) 9164.1675 found 9164.1882; 10 
[00117] Fig 8f is a HRMS(LQT-ESI) mass spectra of PMO-SMCC. Mass calculated for 
C344H513N154O113P25
 (M) 9383.2570 found 9383.2704; 
[00118] Fig 8g is a HRMS(LQT-ESI) mass spectra of PMO-CP8M. Mass calculated for 
C418H638N172O129P25S
+ (M+H)+ 10937.1806 found 10937.2377; 
[00119] Fig 8h is a HRMS(LQT-ESI) mass spectra of NF-PMO-CP8M. Mass calculated 15 
for C393H619N172O121P25S 
 (M) 10490.0372 found 10490.2268; 
[00120] Fig 8i is a HRMS(LQT-ESI) mass spectra of PMO-HP8M. Mass calculated for 
C417H626N173O127P25 
 (M) 10863.1285 found 10863.0716; 
[00121] Fig 8j is a LRMS(API-ES) mass spectra of FITC 3+ (CP8M-3). Mass calculated 
C92H132N18O20S
2+ (M+2H)2+ 920.5 found 921.0; 20 
[00122] Fig 8k is a LRMS(API-ES) mass spectra of FITC 2+ (CP8M-2). Mass calculated 
C92H131N17O20S
2+ (M+2H)2+ 913.0 found 913.6; 
[00123] Fig 8l is a LRMS(API-ES) mass spectra of FITC 1+ (CP8M-1). Mass calculated 
C92H129N14O20S
+ (M+H)+ 1783.1  found 1782.6; 
[00124] Fig 8m is a LRMS(API-ES) mass spectra of FITC + (CP8M-0). Mass calculated 25 
C92H126N11O20S
- (M-H)- 1738.1  found 1738.0; 
[00125] Fig 8n is a HRMS(LQT-ESI) mass spectra of PMO-4-FB. Mass calculated for 
C340H503N153O112P25+ 
 (M-H)+ 9295.1802 found 9295.2168; and 
[00126] Fig 8o is a HRMS(LQT-ESI) mass spectra of PMO-CP8M-NC. Mass calculated 
for C420H642N172O129P25S
+ (M-H)+ 10965.2112 found 10965.2162; 30 
[00127] Figs 9a and 9b demonstrate the comparative conjugation efficiencies of SMCC 
and HNA linker systems; 
[00128] Fig 9a shows the % Conversion of HP8M and PMO-4FB into PMO-HP8M 
analysed by UV spectroscopy. % Conversion was calculated by A350 of the bis-aryl hydrozone 
bond based on the starting reaction concentration of 705 μM. UV profiles of corresponding 35 
starting materials (HP8M and PMO-4FB) and the resulting conjugate (PMO-HP8M); and 
[00129] Fig 9b shows the % isolated yield of PMO-CP8M and PMO-HP8M. 
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[00130] Fig 10a shows florescence microscopy images demonstrating a dose dependent 
increase in DCCPM delivery into a human osteosarcoma cell line (U2OS) maintained in culture, 
without transfection reagent. The biologically active compound was a PMO with a sequence: 
 
Sequence id 1: 5’GGCCAAACCTCGGCTTACCTGAAAT3’ 5 
 
(an antisense reagent targeted to exon 23 of the mouse dystrophin gene, that causes the 
exclusion of exon 23 during mRNA splicing maturation); the bi-functional linker was a 
PEGylated SMCC; and the StaP was RKF-S5-RLF-S5. This configuration of DCCPM is 
depicted as PMO-CP8M in the subsequent figs; unconjugated PMO acts as a control. All 10 
compounds were added to U2OS cells maintained in culture, without transfection reagent for 4 
hours; 
[00131] Fig 10b is a graphical representation of the delivery of PMO and PMO-CP8M into 
a human osteosarcoma cell line (U2OS) maintained in culture without transfection reagent; 
[00132] Fig 11 is the analysis of PMO uptake into HEK293T cells by flow cytometry. Cells 15 
were incubated without PMO or with 1 µM PMO, 1 µM PMO-C8M or 1 µM PMO-CP8M-NC (all 
fluorescein-labelled) at 37ºC for 4 hours. Fluorescence was measured after washing the cells 
with PBS. 
[00133] Fig 12a shows flow cytometry analysis of HEK293T cells treated with FITC+3 
(CP8M3), FITC+2 (CP8M-2) and FITC+1 (CP8M-1) without transfection reagent for 4 hours;  20 
[00134] Fig 12b shows flow cytometry analysis of HEK293T cells treated with FITC+3 
(CP8M3), FITC+2 (CP8M-2) and FITC+1 (CP8M-1) without transfection reagent for 4 hours. 
The graph represents mean fluorescent intensity of FL1; 
[00135] Fig 13 shows fluorescence microscopy images either 5M PMO-CP8M or 5M 
PMO delivery into a mouse cell line that harbours the mdx mutation of the dystrophin gene (H2K 25 
mdx) maintained in culture, without transfection reagent, in which the PMO has a fluorescent 
label.  
[00136] Fig 14 shows an agarose gel electrophoresis image demonstrating that exon 
exclusion of the mouse dystrophin exon 23 is restricted to H2K mdx cells that have been 
transfected with 5M PMO-CP8M but not those treated with 5M PMO alone, in which the 30 
PMOs have a fluorescent label. 24 hours after incubation with PMO-CP8M or PMO, H2K mdx 
cells were recovered and RNA isolated. The RNA was reversed transcribed and an amplification 
between exon 20 and 26 of the mouse dystrophin gene, followed by a nested amplification 
between exon 20 and 26 was performed to yield a full length product of 901 bp fragment if exon 
23 is present or 688bp fragment if exon 23 is excluded;   35 
[00137] Fig 15 shows immuno-cytochemical staining for dystrophin from Tibialis anterior 
muscles of mdx mice following a single intramuscular injection of either 2.2 nmol PMO-CP8M or 
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2.2nmol PMO into the Tibialis anterior muscle (dose in respect of molarity of PMO). Muscles 
were recovered 7 day post administration; 
[00138] Fig 16 shows a graphical representation of the number of skeletal muscle fibre 
being positive for an immuno-cytochemical staining for dystrophin from Tibialis anterior muscles 
of mdx mice injected with either 2.2 nmol PMO-CP8M or 2.2nmol PMO. All dose are given in 5 
respect of the molarity of PMO;  
[00139] Figs 17 a-d show immuno-cytochemical staining for dystrophin from skeletal 
muscles of mdx mice:  
[00140] Fig 17a is from the diaphragm following a single intraperitoneal injection of 1 
mol/kg PMO-CP8M or 1 mol/kg PMO [* denotes non fluorescent labelled PMO]. Muscles 10 
were recovered 7 days post administration; 
[00141] Fig 17b is following multiple intravenous injections - total 4.4 mol/kg PMO-
CP8M or 4.4 mol/kg PMO; 
[00142] Fig 17c is following multiple intraperitoneal injections - total 10.9 mol/kg PMO-
CP8M or 10.9 mol/kg PMO; and 15 
[00143] Fig 17d is a graphical representation of the number of skeletal muscle fibre being 
positive for an immuno-cytochemical staining for dystrophin following intraperitoneal 
administration. All dose are given in respect of the molarity of PMO [* denotes non fluorescent 
labelled PMO]. Muscles were recovered 14 days post administration; 
[00144] Figs 18a-c show immuno-cytochemical staining for dystrophin from heart 20 
muscles; 
[00145] Fig 18a is of mdx mice following a single intraperitoneal injection of 1 mol/kg 
PMO-CP8M or 1 mol/kg PMO. Muscles were recovered 7 days post administration; 
[00146] Fig 18b is following multiple intraperitoneal injections - total 7.6 mol/kg PMO-
CP8M or 7.6 mol/kg PMO. Muscles were recovered 14 days post administration;  25 
[00147] Fig 18c is following multiple intraperitoneal injections - total 10.9 mol/kg PMO-
CP8M or 10.9 mol/kg PMO;  
[00148] Fig 18d is a graphical representation of the number of cardiac muscle fibre being 
positive for an immuno-cytochemical staining for dystrophin following a multiple intraperitoneal 
injections - total 7.6 mol/kg PMO-CP8M or 7.6 mol/kg PMO; and 30 
[00149] Fig 18e is a graphical representation of the number of cardiac muscle fibre being 
positive for an immuno-cytochemical staining for dystrophin following multiple intraperitoneal 
injections - total 10.9 mol/kg PMO-CP8M or 10.9 mol/kg PMO. All dose are given in respect 
of the molarity of PMO [* denotes non fluorescent labelled PMO]. Hearts were recovered 14 
days post administration; 35 
[00150] Fig 19 shows immuno-cytochemical staining for dystrophin from heart muscles of 
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mdx mice following intraperitoneal injections of PMO-CP8M with a total cargo size of 8.7 KDa 
and PMO-CP8M with total cargo size of 9.2 KDa. Hearts were recovered 14 days post 
administration; 
[00151] Fig 20 shows immuno-cytochemical staining for dystrophin from the cerebellum 
of mdx mice following a single intraperitoneal injection of 1 mol/kg PMO-CP8M or 1 mol/kg 5 
PMO. All dose are given in respect of the molarity of PMO [* denotes non fluorescent labelled 
PMO]. Cerebella were recovered 7 days post administration; and  
[00152] Fig 21 demonstrates in vivo liver cell uptake of fluorescein-labelled PMO after 
intravenous administration of PMO or PMO-HP8M to mdx mice (single intravenous injection, 1 
µmol/kg, analysed 2 weeks post-injection). Un-injected mdx mice were used as a negative 10 
control.  
 
DETAILED DESCRIPTION 
 
[00153] The invention is illustrated with reference to a single example which proves the 15 
benefit of the claimed invention. 
[00154] An exemplary drug carrying cell penetrating molecule (DCCPM) was produced 
with a FITC label in order to demonstrate cellular uptake (Example 1). 
[00155] The exemplary DCCPM comprises:  
i) a biologically active compound (BAC) – (see Table 4 for non-limiting examples); 20 
ii) a cell penetrating agent (CPA) which is a stabilized peptide (See Table 2 for non-
limiting examples); and  
iii) a bi-functional linker (BFL) (see Table 5 for non-limiting examples). 
[00156] The three components forming the DCCPM are described in more detail below, 
although as illustrated in Fig 5, the BAC and CPA can be linked directly (Fig 6). 25 
 
1. The Biologically Active Compound. 
  
[00157] The biologically active compound is any compound that can exert a biological 
effect within a biological cell. Preferably, though not essentially, the BAC is one which will 30 
impact on the expression of one or more endogenous or exogenous genes. Examples include 
nucleic acids, DNAzymes, ribozymes, aptamers and pharmaceuticals. Preferred biologically 
active compounds for use in the present invention include electrically neutral oligonucleotides 
(charge -1 to +1 at physiological pH – about 7.5) such as polynucleic acids (PNAs) or PMOs or 
their modified derivatives that might impart a small electric charge (either positive or negative). 35 
[00158] The biologically active compound may be used as a steric blocking compound to 
suppress or enhance: i) RNA splicing; ii) protein translation or iii) other nucleic acid:nucleic acid 
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or nucleic acid:protein interactions, altering the gene expression of endogenous or exogenous 
(pathogen derived) genes. 
[00159] The hybridisation of ON’s to specific RNA sequence motifs prevents correct 
assembly of the spliceosome, so that it is unable to recognise the target exon(s) in the pre-
mRNA and hence excludes these exon in the mature gene transcript. Exclusion of an in-frame 5 
exon can lead to a truncated yet functional gene product; exclusion of an out of frame exon 
results in a frame-shift of the transcript, potentially leading to a premature stop codon and a 
reduction in the target gene expression level.  
[00160] Additionally, ON’s can be designed to target 5’ translation initiation start sites of 
endogenous or viral gene transcript(s) to prevent binding of the translational machinery. Using 10 
ASO to suppress viral translation is a well-established technology and has progressed into 
clinical trials for viral haemorrhagic fevers such as Marburg and Ebola. 
[00161] Also, ON can be designed to target 3’ untranslated region of an endogenous 
transcript that alters the stability of the transcript. Such targets include, and are not limited to, 
poly adenylation and/or cleavage sites of the transcript. 15 
[00162] Also, ON can be designed to form aptamers such that the secondary and tertiary 
structures can bind proteins or other cellular targets thus impacting on specific gene expression 
levels.  
[00163] Non-limiting exemplary ON chemistries are illustrated in Table 4.  
[00164] In the non-limiting example illustrated, the target is exon 51 of the dystrophin 20 
gene and comprises the sequence:  
 
Sequence id 2: 5’CUCCAACAUCAAGGAAGAUGGCAUUUCUAG3’ 
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2. The cell penetrating agent (CPA) which is a stabilized peptide 
 
[00165] The cell penetrating agents of the invention are stabilized peptides. 
[00166] The peptides may be stabilized by stapling, to form a stapled peptide (StaP), or 
by stitching to form a stitched peptide (StiP)  30 
[00167] All-hydrocarbon staples and stitches may confer a property, e.g. an α-helical 
structure, protease resistance, cellular penetrance, and biological activity. 
[00168] Non-limiting examples of stapled and stitched peptide sequences are illustrated 
in Table 2 and include peptide sequences including S5, S8 and B5 (as defined in Table 2). 
[00169] Stabilisation of e.g. the α-helical structure can be achieved by, for example, a 35 
ring-closing metathesis and may be catalysed by a variety of ruthenium catalysts including 
Grubbs generations 1 and 2 and Grubbs-Hoyveda generations 1 and 2. 
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[00170] All the peptide components (amino acids, unnatural amino acids, 
unstapled/unstitched, partially stapled/stitched and stapled/stitched peptides) may exist in 
specific geometric or stereoisomeric forms. All compounds include cis- and trans-isomers, (R)- 
and (S)-enantiomers, diastereoisomers and racemic mixtures thereof. 
[00171] Preferred isomer/enantiomers will be enriched to give a greater proportion of one 5 
particular isomer or enantiomer. Embodiments thereof may be made of greater than 90%, 95%, 
98% or 99%, by weight, of a preferred isomer/enantiomer. 
[00172]  Non-limiting examples of unnatural amino acids used in stabilising a peptide 
structure are illustrated in Table 1. 
[00173] In one embodiment the applicant employs α,α-disubstituted unnatural amino 10 
acids bearing all-hydrocarbon tethers (e.g. α-methyl,α-pentenyl glycine). 
[00174] For single turn stapling, one embodiment could employ a (S)-pentenylalanine 
(S5) at, e.g. i, i + 4 positions, and in another embodiment, for double turn stapling, a 
combination of either R-octenylalanine/S-pentenylalanine (R8/S5) or S-octenylalanine/R-
pentenylalanine (S8/R5) at e.g. i, i + 7 positions can be used. The same pairings can be used to 15 
install more than one staple within a given peptide template. S5 can be substituted at i, B5 at 
postion i + 4 positions, and S8 can be been substituted at i, i +4, i + 11 positions to generate 
stitched peptides. The S5 configured amino acid and its enantiomer R5, or S8 configured amino 
acid and its enantiomer R8, differ only in the opposite stereochemical configuration of the staple 
they bear. 20 
[00175] Based upon the inclusion of a single or a double turn staple, peptides may 
comprise of one or more of the sequences in Table 2. Based upon the specific peptides shown 
in Table 2, a person skilled in the art can easily envisage peptides with 3, 4, 5 or more turn 
stabilising staples. 
[00176] The hydrocarbon bridge may be composed of a double hydrocarbon bond or a 25 
single hydrocarbon bond. 
[00177] In one embodiment the cell penetrating agent has a stitch or staple peptide 
comprising the sequence RFK-S5-RLF-S5. 
[00178] In another embodiment the peptide is a branched stapled peptide. The branched 
stapled peptide comprises of 2 or more chains of peptides. Branched peptides may be formed 30 
using any method know to the art; in one embodiment a lysine residue is used to branch two 
peptide chains. 
[00179] Functional derivatives of disclosed peptide sequences could be used. Functional 
derivatives may have representative fragments or homologues or peptides that include 
insertions to the original peptide. Typical derivative would have 70%, 80%, 90% or more of the 35 
original peptide sequence and may have up to 200% of the number of amino acids of the 
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original peptide. The derivatives would be used to enhance the delivery of a biologically active 
compound. 
[00180] Peptide sequence can include modified amino acids to include functional groups 
that permit the addition of other moieties. Non-limiting examples of such moieties include an 
acetyl, a cholesterol, a fatty acid, a polyethylene glycol, a polysaccharide, an aminoglycan, a 5 
glycolipid, a polyphenol, a nuclear localising signal, a nuclear export signal, an antibody and a 
targeting molecule. 
 
3. Bi-functional Linker 
 10 
[00181] A bi-functional linker may be used to link the BAC to the CPA. 
[00182] Preferred linkers will link between, for example, an amine group on the BAC and 
a sulfhydryl (thiol) group (usually a cysteine residue) on the CPA terminus. Examples of 
substrates to achieve this include, but are not limited to, SMCC (succinimidyl 4-(N-
maleimidomethyl)cyclohexane-1-carboxylate), AMAS (N-α-maleimidoacet-oxysuccinimide ester, 15 
BMPS (N-β-maleimidopropyl-oxysuccinimide ester), GMBS (N-γ-aleimidobutyryl-oxysuccinimide 
ester), DMVS (N--maleimidovaleryl-oxysuccinimide ester, EMCS (N- ε-malemidocaproyl-
oxysuccinimide ester), and LC-SMCC (Succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-
carboxy-(6-amidocaproate) as exemplified in Table 5. 
[00183] Another preferred linker system is hydrazynal nicotinic acid (HNA), however if the 20 
BAC is a PMO, the PMO is modified to incorporate 4 formyl benzioic acid.  
[00184] Other linkers such as DSG (disuccinimidyl gluterate) and DSCDS (disuccinimidyl-
cyclohexl-1,4-diester) will include the ability to link the 5’-amino group of the BAC to the N-
terminus of the CPA (Table 5, entries 8 and 9).  
[00185] Linkers may include other elements that confer a desirable property on the 25 
DCCPM e.g. spacer between ON and CPA or an element that will enhance solubility, for 
example a PEGylated element as illustrated in Figs 5c and 5d. Non-limiting examples are 
shown in Table 5.  
[00186] The biologically active compound is covalently attached to the chimeric cell 
delivery peptide. Again, this can be done using any method known in the art. Preferably, the cell 30 
delivery peptide is attached to the biologically active compound by means of a disulphide bridge 
or a thiol maleimide linker e.g. SMCC; the attachment may be by means of an amide linker or 
an oxime linker or a thioether linker. 
 
 35 
EXAMPLE 1:  (Proof of principle) 
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DCCPM to enhance RNA steric blocking in treating Duchenne muscular dystrophy 
(DMD). 
 
Introduction 
[00187] Duchenne muscular dystrophy (DMD) is the most common inherited lethal 5 
childhood disease in the world, with a worldwide incidence of approximately 1 in 4000 live 
births33. This severe muscle-wasting disorder is caused in the majority of families by gene 
mutations leading to disruption of the reading frame and premature truncation of the protein 
dystrophin34,35. 
[00188] RNA splicing suppression of the DMD transcript has particular promise. The 10 
hybridisation of ASOs to specific RNA sequence motifs prevents correct assembly of the 
spliceosome, so that it is unable to recognise the target exon(s) in the pre-mRNA and hence 
excludes them in the mature gene transcript. ASO-mediated RNA splicing suppression resulting 
in the re-expression of a truncated, yet functional dystrophin protein has been demonstrated in 
vitro and in the pre-clinical mdx mouse model29,36-41, which led to clinical development 15 
programs8,13. 
[00189] Although intravenously administered PMOs have demonstrated a dose-
dependent increase in dystrophin re-expression with some functional benefit13,42, skeletal 
muscle dystrophin restoration is still very variable between patients after many multiple 
administrations. Importantly, many other target tissues (e.g. brain and heart) remain refractory 20 
to PMO transfection even when repeat administration or high dose strategies are employed27-29.  
[00190] To date unmodified CPA conjugation improves PMO bio-distribution and serum 
stability30-32, however toxicity is still a major roadblock for pipeline development19.  
[00191] Applicant hypothesised that a CPA based upon a stabilized e.g. StaP (or StiP) 
conjugated to a PMO known to cause RNA splicing suppression of the DMD transcript, would 25 
lead to a greater level of dystrophin restoration and re-expression of dystrophin in tissues 
refractory to naked PMO without the potential for CPA related toxicity. 
 
Materials and Methods 
 30 
Nuclear Magentic Resonance (NMR) Analysis of StaP 
 
[00192] 1H NMR spectra was recorded using a Bruker Avance III 500 (500 MHz) 
spectrometer. Samples were dissolved in H2O with 10% D2O and 10 mM sodium acetate.  
[00193] NOESY spectra were recorded with a 12626.263 Hz sweep width, 4096 complex 35 
points (DQD acquisition mode) in the direct dimension and 1024 indirect points (States-TPPI 
acquisition mode). A NOESY mixing time of 250 ms was used to provide cross peaks with high 
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signal to noise while largely avoiding spin diffusion. A pre-saturation pulse on water and a 3-9-
19 pulse sequence with 20% Z-gradients (4,5) aided solvent suppression. TOCSY spectra were 
recorded with the same spectral width and resolution as the NOESY with a homonuclear 
Hartman-Hahn transfer using the MLEV17 sequence for an 80 ms mixing time (6). Two power 
levels were used for excitation (3 dB) and spinlock (12.2 dB). Water suppression was achieved 5 
as with the NOESY. 
 
High Resolution Mass Spectroscopy 
 
[00194] High-resolution mass spectra were recorded on a Thermo scientific LQT Orbitrap 10 
XL under electron spray ionization conditions (ESI) or where indicated under Atomospheric 
Pressure Ionisation (API) condition. 
 
Circular Dichroism (CD) Spectroscopy 
 15 
[00195] CD analysis was performed on an Applied Photophysics Chirascan Circular 
Dichroism spectrometer. Samples were dissolved in D2O at 0.125 W/W% and data acquired in 
triplicate at room temperature and subsequently averaged and smoothed using built in qCD 
software. Graphs were plotted by subtracting a blank D2O spectrum from the acquired data to 
provided blank correction. 20 
 
Synthesis of PMO-CP8M and NF-PMO-CP8M 
 
[00196] PMO (22.2 mg, 2.1 μM) was dissolved in PBS (400 μL, 1 x) and incubated at 
room temp after the addition of SMCC linker (6 mg, 18 μM, 9x excess) dissolved in MeCN 100 25 
μL. After 45 mins the mixture was desalted using sephadex g25 hydrated in a PBS 1x and was 
also used as the eluent. RCM-C-PEG-8Mer (3 mg, 2.5 μM) was mixed immobilised TCEP (750 
μL) for 1 h. The SMCC modified PMO was then desalted into PBS/MeCN (500 μL 4:1) and 
immediately the peptide was eluted from the immobilised TCEP and stirred at room temp for 3 
hours before purification on a Waters HLB column. 30 
[00197] The solution was loaded onto 4 HLB columns, and washed with milliQ water to 
remove any salts then 20% MeCN in water and finally PMO-CP8M was removed with 50% 
MeCN in water. The MeCN content was reduced by rotary evaporation and the conjugate 
subsequently freeze dried to yield the final lipholysed compound. 
 35 
Synthesis of PMO-HP8M 
Modification of PMO to PMO-4FB.  
 30 
 
[00198] 4-FB (250 mg, 1.5 mM) was dissolved in DMF with COMU (1.2 g, 2.6 mM) and 
NHS (230 mg, 2.0 mM) and stirred for a few mins. Nb, 4-FB did not fully dissolve until DIEA was 
added. DIEA (0.54 mL 3.0 mM) was then added upon which the reaction mixture changed from 
colourless to pale yellow/orange. The reaction mixture was stirred for 1 h and monitored by TLC 5 
using 5% MeOH in DCM. The mixture was separated over DCM to remove DMF then purified 
by flash chromatography using DMC to elute the top spot staining positive with 2,4 DNP. 
Product was collected as an off white solid 112 mg (30 %). 
[00199] PMO (30.4 mg, 3 μM) was added to a solution of 4-FB and dissolved in 
Carbonate buffer:MeCN (50% MeCN) and NHS activated 4-FB (10 mg, 32 μM) was added and 10 
stirred overnight. The mixture was then desalted using sephadex G25 superfine with 
water:MeCN as an eluent. MeCN was removed by rotary evaporation and the remaining eluent 
was then freeze dried. Freeze dried product yielded 24 mg 83% yield. 
 
Conjugation of PMO-4FB to HP8M 15 
 
[00200] HP8M was dissolved in milliq ultra pure water (100 μL) to give a solution of 12 
mg/mL. Aldehyde modified PMO (7 mg, 0.76 μM) was dissolved in water/MeCN (300 μL, 1:1) 
and desalted using sephadex G25 superfine and water/MeCN (1:1) as the eluent. The collected 
fraction was then diluted to 1 mL total volume in water:MeCN mix (1:1) and PMO content was 20 
analysed by UV/vis and found to be 6.5 mg/mL or 705 μM. HNA peptide and Analine (10 mM 
final conc) was then added and UV/vis monitored for evidence of A354 and used to calculate the 
conjugation of PMO to peptide. 
 
PMO and Peptide Synthesis 25 
 
[00201] PMO were synthesised with a 5’ amine group and 3’ fluorescein isothiocyanate 
(FITC) label and purified >90% by Genetool LLC (Philomath, Oreg. USA). All peptides were 
synthesized following an established protocol using standard Fmoc-peptide chemistry on Rink 
amide MBHA resin. The coupling reactions were performed by the addition of a mixture of 10 30 
equivalents of the amino acids, 9.9 equivalents of HCTU and 20 equivalents of DIPEA in NMP 
(equivalents relative to initial loading of Rink amide MBHA resin). The reactions were allowed to 
proceed for at least one hour. Coupling of non-natural amino acids (R/S5, R/S8 or B5) was 
performed with 4 equivalents of the amino acid, 3.9 equivalents of HCTU and 10 equivalents of 
DIPEA in NMP for two hours. The ring closing metathesis reaction of the olefin-containing non-35 
natural amino acids was facilitated with Grubbs I catalyst (benzylidene-
bis(tricyclohexylphosphine)-dichlororuthenium) dissolved to approximately 10mg/mL in 1,2-
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dichloroethane (DCE) for two hours under nitrogen bubbling. Subsequently, excess catalyst was 
washed from the resin with DCE and then coupled with an N-terminal FITC. Upon completion, 
peptides were simultaneously cleaved from the resin and de-protected using a cleavage cocktail 
containing 95% TFA, 2.5% TIS and 2.5% water. Crude peptides were dissolved in 50% 
acetonitrile/water, passed through a 0.2 μm syringe filter, and purified by reverse phase HPLC 5 
using a C-18 column (Agilent, Palo Alto, CA). Compound identification and purity was assessed 
using coupled LC/MS (Agilent, Palo Alto, CA). Purified fractions were pooled and evaporated to 
remove acetonitrile and trace TFA by Speedvac and then lyophilized to dryness. A non-ring 
closed peptide was also produced as a control. 
 10 
Cell Culture and Transfection 
 
[00202] U2OS cells (Human osteosarcoma) were cultured in high glucose DMEM 
supplemented with 10% foetal calf serum (Sigma, UK) at 37oC under an 8% CO2/92% air 
atmosphere.  15 
[00203] H2K mdx mouse myoblasts were cultured at 33°C under a 8% CO2/92% air 
atmosphere in high-glucose DMEM supplemented with 20% foetal calf serum, 0.5% chicken 
embryo extract (PAA laboratories Ltd, Yeovil, UK), and 20 units/ml γ-interferon (Roche applied 
science, Penzberg, Germany). Cells were then treated with trypsin and plated at 8x104/cm2 in 
24-well plates coated with 0.1mg/ml ECM gel (Sigma). H2K mdx cells were transfected 24 h 20 
after seeding with treatment in a final volume of 0.2 ml of normal growth media. Following 4 
hours of transfection, the PMO or PMO-SAP was removed and replaced with DMEM 
supplemented with 5% horse serum. Fluorescence and RNA extraction was performed 48 hours 
post transfection. 
[00204] HEK293T cells (Human embryonic kidney) were cultured in high glucose DMEM 25 
supplemented with 10% foetal calf serum (Sigma, UK) at 37oC under an 8% CO2/92% air 
atmosphere.  
[00205] U2OS cells were incubated with PMO or PMO-CP8M at increasing concentration 
(0.5M, 1.0M, 5.0M and 10M) with any facilitation transfection reagent; H2K mdx mouse 
myoblasts were incubated with PMO or PMO-CP8M at 5.0M:  HEK293T cells were incubated 30 
with CP8M (1.0M, 10M and 100M) and PMO, PMO-CP8M-NC, PMO-C8M at 1.0M. Levels 
of fluorescence was quantified at 494 nm to determine relative entry of respective compounds 
by microscopic or flow cytometry methodologies. 
 
RNA Extraction and nested RT-PCR Analysis 35 
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[00206] Total RNA was isolated from H2K mdx mouse myoblasts cells (RNeasy, Qiagen, 
UK). The RNA was reversed transcribed (nanoscript2, Primer Design UK) and an amplification 
between exons 20 and 26, followed by a nested amplification between exon 20 and 26 was 
performed to yield a full length product of 901 bp or 688bp if the mouse dystrophin exon 23 was 
excluded. Products loaded in a 1% agarose gel (buffered with tris acetate 40mM and 1mM 5 
ethylenediaminetetraacetic acid). 
 
Animals 
 
[00207] mdx mice, with access to chow and water ad libitum, were used in all 10 
experiments. All experiments were carried out in the Animal unit, School of Biological Science, 
University of Reading, Reading, UK according to procedures authorized by the UK Home Office. 
Mice were killed by CO2 inhalation or cervical dislocation at desired time points, and muscles 
and other tissues were snap-frozen in liquid nitrogen-cooled isopentane and stored at −80°C. 
 15 
Administration of PMO or PMO-CP8M 
 
[00208] Intramuscular administrations: Tibialis anterior muscles of mdx mice were 
injected with either 2.2nmol PMO or 2.2 nmol PMO-CP8M under isoflurane anaesthesia. 
Systemic administration: mdx mice were subject to a single or repeated intraperitoneal 20 
injections of PMO or PMO-CP8M (or non-fluorescently labelled variants) at doses ranging from 
1 mol/kg to 10.9 mol/kg total delivery; alternatively, mdx mice were subject to single or 
repeated intravascular injections of PMO or PMO-CP8M ranging from 1 mol/kg to 4.4 mol/kg 
total. A series of tissues were recovered at the end of the experiment that included skeletal 
muscle, heart, brain and liver. 25 
 
Histology and Immuno-cytochemistry 
 
[00209] For skeletal muscle, heart and brain, 10M cryosections were cut and dystrophin 
protein was detected using rabbit polyclonal antibody to dystrophin (ab15277; Abcam, 30 
Cambridge, UK). Routine haematoxylin and eosin staining was used to assess general 
pathology and morphology. For liver, 10M cryosections were dried and embedded in 
fluorescence-compatible mounting medium (Dako), and general fluorescence was assessed 
microscopically at 494 nm. 
 35 
Flow cytometry 
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[00210] Uptake of fluorescently-labelled PMO was determined by flow cytometry using an 
Accuri C6 flow cytometer. PMO-transfected cells were released with trypsin, washed in PBS 
and kept on ice before analysis. Cell fluorescence in single live cells was determined using 
FlowJo software after appropriate gating. Untreated cells were used to establish gating settings 
for the determination of the % fluorescein-positive cells. 5 
 
Statistical Analysis 
 
[00211] All data are reported as mean values ±SEM. Statistical differences between 
treatment groups and control groups were evaluated by SigmaStat (Systat Software, UK) and 10 
student's t test was applied. Significance was accepted for p-values<0.05. 
 
Results 
 
[00212] Circular dichroism and the nuclear magnetic resonance data confirmed that the 15 
ordered structure of the peptides was as expected and that the stapled peptides adopted an -
helical structure (Fig 4). 
[00213] The conjugation of PMO-SMCC with a CPP to form PMO-CP8M has consistently 
yielded an efficiency of 10%. Surprisingly, adopting a conjugation based upon a PMO modified 
to incorporate 4 formyl benzioic acid and hydrazynal nicotinic acid (HNA) incorporated into the 20 
terminal end of the CPP, increased the efficiency of conjugation to yield PMO-HP8M at 59% 
(Fig 9). 
[00214] PMO was conjugated to the bi-functional linker (a PEGylated SMCC) and a CPP 
(RKF-S5-RLF-S5) as confirmed by mass spectrometry (Fig 7). Subsequently PMO and PMO-
CP8M were transfected into a standard cell line (U2OS) to determine if the CP8M conferred 25 
enhanced cell entry to the cell. Naked PMO were refractory to cell entry, giving only a 
background fluorescence signal, compared to a dose dependant increase in fluorescence with 
PMO-CP8M (Figs 10a and 10b). The lack of signal above background does not allow statistical 
analyses of the comparative increase in fluorescence, but clearly demonstrated that without the 
CP8M conjugation, PMO did not enter the cell. 30 
[00215] Transfection experiments conducted in the HEK293T human embryonic kidney 
cells again demonstrated that PMO was refractory to cell entry. Importantly, a non-ring closed 
variant of CP8M (termed CP8M-NC) also did not result in significant cell entry above that of 
PMO alone. However a ring closed variant that contains the core sequence RKF-S5-RLF-S5 
demonstrated that when conjugated to a fluorescently labelled PMO (to form PMO-C8M), that 35 
the PMO was now efficiently taken into cells (Fig 11). This confirms that the shape imposed 
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upon the peptide sequence, following a ring closing metathesis, is important to facilitate cellular 
entry of a DCCPM in which the BAC is an ON, more specifically a PMO.   
[00216] The formal charge of CP8M is +3 at physiological pH. We also provide data 
demonstrating that reducing the formal charge within this sequence still leads to a surprising 
and significant cellular entry of CP8M variants with formal charges of +2 (CP8M-2) and +1 5 
(CP8M-1) (Figs 12a and 12b), particularly at lower concentrations. The reduction in charge 
leads to solubility issues which account for the failure of a dose dependent increase, unlike that 
observed with CP8M.  Alternative excipients or manipulations of the peptide as highlighted in 
Table 5 and Table 6 are likely to overcome these solubility issues.  
[00217] When transfection experiments were conducted in the H2K mdx mouse 10 
myoblasts cells, it confirmed the finding that PMO are refractory to muscle cell entry, which was 
overcome with the conjugation of CP8M (Fig 13) and that the CP8M mediated delivery of PMO 
resulted in the steric blockade of RNA editing of the dystrophin transcript, such that exon 23 
was excluded from the transcript (Fig 14). Again, the lack of exon exclusion from the PMO only 
samples precludes comparative statistical analyses; but highlights that exon exclusion, resultant 15 
from entry of a PMO, only occurs when the PMO is conjugated to CP8M. 
[00218] In order to determine if CP8M hindered the biological activity of the PMO, direct 
intramuscular administrations (2.2 nmol) were conducted into the Tibialis anterior muscle of mdx 
female mice, with muscle recovered 7 days post-administration. The percentage of dystrophin 
re-expression was equivocal between the PMO-CP8M (805.75) and the naked PMO (762.25) 20 
with no statistical significant difference (n=4, p=0.863; Fig 15 and Fig 16). Thus it was 
determined that CP8M does not confer any steric hindrance to the biological activity of the 
PMO. 
[00219] Systemic administrations of PMO-CP8M and PMO were conducted in mdx mice 
to determine if the CP8M moiety enhanced cell entry into skeletal muscle. Varying sub-optimal 25 
amounts (totally 1 mol/kg, 4.4 mol/kg, 10.9 mol/kg) were administered by either 
intraperitoneal or intravenous injections, and diaphragm and/or Tibialis anterior (TA) muscle 
recovered 7 days post-administration. After a single intraperitoneal administration of 1 
mol/kg  the diaphragm muscle gave more dystrophin positive fibres after PMO-CP8M 
treatment compared to the PMO control group (Fig 17a, n=1). In tibialis anterior muscles, 30 
intravenous (4.4 mol/kg; n=3) data was equivocal between groups (Fig 17b and Fig 17d, 
p=0.201), as was the intraperitoneal (10.9 mol/kg; n=4) data (Fig 17c and Fig 17d, p=0.886). 
[00220]  (4.4 mol/kg; n=3) data was equivocal between group (Fig 17b and Fig 17d, 
p=0.201), as was the intraperitoneal (10.9 mol/kg; n=4) data (Fig 17c and Fig 17d, p=0.886). 
[00221] Systemic intraperitoneal administrations of PMO-CP8M and PMO were 35 
conducted in mdx mice to determine if CP8M enhanced cell entry (Figs 18-21). A series of 
 35 
tissues was recovered and frozen 1 or 2 weeks post-administration (skeletal muscle, heart, 
brain and liver).  
[00222] A single low dose of PMO or PMO-CP8M (1 µmol/kg) was administered (n=1 per 
group) and tissues recovered 7 days post-administration. Dystrophin-positive heart muscle 
fibres were detected after PMO-CPM8, but not PMO administration (Fig 18a).  5 
[00223] In addition, we carried out repeated intraperitoneal administrations into mdx 
mice. Intraperitoneal injections of PMO-CP8M (without fluorescent label) totalling 7.6 µmol/kg 
over 4 days (n=4 per group) lead to a significant increase in dystrophin-positive heart muscle 
fibres 2 weeks post-administration compared to injection of an equimolar amount of PMO 
(340±69 vs 57±17 fibres, p<0.01; Figs 18b & 18d).  10 
[00224] Furthermore, Applicant carried out intraperitoneal administration of PMO or 
PMO-CP8M, totalling 10.9 µmol/kg over 2 days (n=4 per group). Again, administration of PMO-
CP8M lead to a significantly higher number of dystrophin-positive heart muscle fibres compared 
to administration of PMO (680±163 vs 33±8 fibres, p<0.05; Figs 18c & 18e).  
[00225] PMO-peptide conjugates of both 8.7 kDa and 9.2 kDa were successfully 15 
delivered to heart muscle fibres as evidenced by the induction of dystrophin re-expression in the 
hearts of mdx mice (Fig 19, n=4).    
[00226]    A single low dose (1 µmol/kg) intravenous administration of PMO-CP8M, but 
not PMO (both without fluorescent label), led to recovery of dystrophin expression in the 
Purkinje cells of mdx mouse cerebellum (Fig 20; n=1 per group). No dystrophin expression was 20 
observed in the PMO control. 
[00227] A single low dose (1 µmol/kg) intravenous administration of PMO-HP8M led to 
increased hepatocyte fluorescence in the vicinity of blood vessels two weeks post-
administration compared to administration of PMO (Fig 21; n=1 per group), implying increased 
uptake of PMO-HP8M in hepatocytes. 25 
 
 
Conclusion 
 
[00228] From the data generated it can be seen that the conjugation of a CPA, stabilized 30 
by stapling, to a BAC (in the form of a PMO), via a BFL, facilitates entry of the PMO into a cell. 
The StaP CPA facilitated PMO entry in both in vitro and in vivo assay systems. 
[00229] Applicant’s data presents evidence that modified linker systems based on HNA 
and 4 formyl benzioic acid improve the efficiency of conjugation between a BAC and CPA. 
[00230] Surprisingly, variants of CPA in which the formal charge is reduced demonstrate 35 
enhanced cell entry at lower concentrations. This will have important sequelae with respect to 
improving the toxicological profile of CPA, more specifically a CPP. 
 36 
[00231] The in vivo model of RNA splicing suppression demonstrated that the biological 
action of an α-helical peptide conjugated PMO is equivalent to naked PMO following 
intramuscular administration, thus determining that no steric hindrance is exerted upon the PMO 
when coupled to an α-helical peptide moiety. 
[00232] The data demonstrates the fact that in the in vivo model of RNA splicing 5 
suppression the stabilized CPA may enhance cell entry into skeletal muscle, particularly at 
lower doses. However PMO are known to enter skeletal muscle without a CPP conjugation. 
[00233] Surprisingly, and very significantly, it has been demonstrated that tissues 
refractory to naked PMO transfection re-express dystrophin protein in both the heart and brain 
(purkinje cell) compartments when the PMO is conjugated with a StaP.  10 
[00234] Applicant further provides evidence that the CPP can facilitate the entry of 
cargoes of different size and mass far beyond that stated in the current state of the art. 
[00235] The repertoire of human and animal diseases that can be addressed is now 
expanded and enhanced due to the increased pharmacodynamics of the PMOs when 
conjugated with a stabilised peptide. Neuromuscular disease, metabolic disease, cancer, age-15 
related degenerative diseases and acquired viral infection can all be targeted. 
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CLAIMS 
 
1. A drug carrying cell penetrating molecule (DCCPM) comprising: 
i. a biologically active compound (BAC), and 
ii. a cell penetrating agent (CPA), which BAC and CPA are linked directly or 5 
via a bi-functional linker (BFL), 
and wherein the CPA is a stabilized peptide (CPP) which has a conformation 
imposed upon it by stapling to form a stapled peptide (StaP) or stitching to form a 
stitched peptide (StiP). 
 10 
2. A DCCPM as claimed in claim 1 wherein the StiP or StaP comprises a cross link 
or bridge between two amino acids of the peptide. 
 
3. A DCCPM as claimed in claim 2 wherein the cross link or bridge comprises two 
components, a hydrocarbon bridge and a terminal methyl group. 15 
 
4. A DCCPM as claimed in claim 2 wherein the peptide comprises at least two un-
natural amino acids bearing all-hydrocarbon tethers (e.g. α-methyl, α-pentenyl 
glycine). 
 20 
5. A DCCPM as claimed in claim 3 wherein CPA is stabilized with a staple or stitch 
incorporating  one or more of: a (S)-pentenylalanine (S5) or its enantiomer (R5), 
a S-octenylalanine (S8) or its enantiomer (R8) or combinations thereof (e.g. R-
octenylalanine/S-pentenylalanine (R8/S5) or S-octenylalanine/R-pentenylalanine 
(S8/R5). 25 
 
6. A DCCPM as claimed in claim 2 comprising a cross link or bridge between one or 
more of the unnatural  amino acids of Table 1. 
 
7. A DCCPM as claimed in claim 6 wherein the stabilized peptide comprises two or 30 
more olefin bearing side chains that are covalently formed. 
 
 
8. A DCCPM as claimed in any of the preceding claims wherein the stabilized 
conformation comprises at least one alpha helix. 35 
 
9. A DCCPM as claimed in any of the preceding claims wherein the stabilized 
conformation comprises at least one beta sheet. 
 
 41 
10. A DCCPM as claimed in any of the preceding claims wherein the stabilized 
conformation comprises at least one alpha helix and one beta sheet. 
 
11. A DCCPM as claimed in any of the preceding claims wherein the BAC is an 
oligonucleotide (ON). 5 
 
12. A DCCPM as claimed in claim 11 wherein the ON is an electrically low charge 
carrying oligonucleotide. 
 
13. A DCCPM as claimed in claim 12 wherein the ON is an electrically neutral charge 10 
carrying oligonucleotide 
 
14. A DCCPM as claimed in claim 12 or 13 wherein the ON is a polynucleic acid 
(PNA) or a phosphorodiamidate morpholino oligonucleotide (PMO). 
 15 
15. A DCCPM as claimed in any of claims 11 to 14 wherein the ON is an anti-sense 
oligonucleotide (AON). 
 
16. A DCCPM as claimed in claim 15 wherein the ON is an anti-sense 
oligonucleotide comprising a chemistry selected from the compounds of Table 4. 20 
 
17. A DCCPM as claimed in claim 11 wherein the BAC is a phosphorodiamidate 
morpholino oligonucleotide (PMO). 
 
18. A DCCPM as claimed in any of the preceding claims wherein the BAC alters the 25 
expression of an endogenous or exogenous gene. 
 
19. A DCCPM as claimed in claim 18 wherein the endogenous gene targets  a 
neuromuscular disease, a metabolic disease, cancer, an age-related 
degenerative disease or an acquired viral infection. 30 
 
20. A DCCPM as claimed in any of the preceding claims wherein the BFL comprises 
a chemistry selected from the chemistries of Table 5. 
 
21.  A DCCPM as claimed in claim 20 comprising an amine to sulphydryl cross linker 35 
containing N- hydroxysuccinimide esters and malemide reactive groups 
separated by a cyclohexane spacer. 
 
 
22. A DCCPM as claimed in claim 20 or 21 wherein the BFL is a succinimidyl 4-(N-40 
maleimidomethyl) cyclohexane-1-carboxylate (SMCC). 
 42 
23. A DCCPM as claimed in claim 1 wherein the BFL is HNA and has been 
incorporated into the terminal end of the CPP. 
 
24. A DCCPM as claimed in claim 23 wherein the BFL is HNA and the ON has been 
modified to incorporate 4 formyl benzioic acid to facilitate covalent conjugation. 5 
 
25. A DCCPM as claimed in claim 22 wherein the SMCC is PEGylated. 
 
26. A DCCPM as claimed in claim 23 of 24 wherein the HNA is PEGylated 
 10 
27. A DCCPM as claimed in claim 20 wherein the CPA is linked to a first end of the 
BFL covalently. 
 
28. A DCCPM as claimed in claim 20 wherein the BAC is linked to a second end of 
the BFL covalently. 15 
 
29. DCCPM as claimed in claim 1 which is of a size greater than 1.5KDa. 
 
30. A method for facilitating the uptake of a biologically active compound (BAC) into 
a cell by the conjugation of the biologically active compound to a cell penetrating 20 
agent (CPA) which is a stabilized peptide which has a conformation imposed 
upon it by stapling to form a stapled peptide (StaP) or stitching to form a stitched 
peptide (StiP) directly or via a bi-functional linker (BFL) to form a drug carrying 
cell penetrating molecule (DCCPM) and presenting said DCCPM to said cell in a 
suitable vehicle.  25 
 
31. A DCCPM as claimed in any of claims 1-29 for use in the treatment of a disease 
requiring alteration of the expression of an endogenous or exogenous gene. 
 
32. A DCCPM as claimed in claim 31 for use in the treatment of neuromuscular 30 
disease, a metabolic disease, cancer, an age-related degenerative disease or an 
acquired viral infection. 
 
33. A DCCPM as claimed in claim 31 for use in the treatment of Duchenne’s 
muscular dystrophy. 35 
 
34. A DCCPM as claimed in claim 33 wherein the DCCPM comprises an AON 
targeting exon 51 of the dystrophin gene. 
 
 43 
35. A method of improving the bioavailability of a drug or BAC comprising linking the 
drug or BAC to a CPP which is a stabilized peptide which has a conformation 
imposed upon it by stapling to form a stapled peptide (StaP) or stitching to form a 
stitched peptide (StiP). 
 5 
36. A method of introducing a drug or BAC to a site which is refractory to the drug or 
BAC in its native state comprising linking the drug or BAC to a CPP which is a 
stabilized peptide which has a conformation imposed upon it by stapling to form a 
stapled peptide (StaP) or stitching to form a stitched peptide (StiP) and 
administering it to a subject.. 10 
 
37. A method as claimed in claim 36 wherein the tissue is one of heart, brain, muscle 
or liver. 
 
38. A method of treating a subject to alter the expression of an endogenous or 15 
exogenous gene comprising administering a DCCPM as claimed in any of claims 
1-29 or 31-34. 
 
39. A composition comprising a DCCPM as claimed in any of claims 1-29 or 31-34 
and one or more pharmaceutically acceptable excipients. 20 
 
40. A composition as claimed in claim 39 which is adapted for administration orally, 
parenterally, intravenously or topically 
 
 25 
 
 
 
 
  30 
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ABSTRACT 
 
The invention relates to improvements in drug delivery and more particularly to the use of Cell 
Penetrating Agents (CPA’s) or Cell Penetrating Peptides (CPP’s) which have been stabilized by, 
for example: i) stapling two amino acids to form Stapled CPP’s (StaP’s) or ii) stitching three or 5 
more amino acids to form stitched CPP’s (StiP’s).These stabilized CPP’s are conjugated to a 
drug or Biologically Active Compound (BAC) directly or via a Bi-Functional Linker (BFL) so that 
the BAC can be carried though a cell membrane by the CPP. The resulting molecules are 
referred to as Drug Carrying Cell Penetrating Molecules (DCCPM’s). The preferred BAC is an 
electrically low charge carrying oligonucleotide such as a phosphorodiamidate morpholino 10 
oligonucleotide (PMO). The invention also relates to a method of facilitating the uptake of a BAC 
into a cell, the use of a DCCPM in the treatment of a disease requiring alteration of an 
endogenous or exogenous gene, a method of improving the bioavailability of a drug or BAC, a 
method of introducing a drug or BAC to a site which is refractory to the drug or BAC in its native 
state, a method of treating a subject comprising administering the DCCPM’s of the invention 15 
and to a pharmaceutical composition comprising the DCCPM and one or more pharmaceutically 
acceptable excipients. 
 
 
 20 
 
